-
Carisma Therapeutics NasdaqGM:CARM Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Location: 3675 Market Street, Philadelphia, PA, 19104, United States | Website: https://www.carismatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-8.288M
Cash
18.83M
Avg Qtr Burn
-14.98M
Short % of Float
0.93%
Insider Ownership
27.76%
Institutional Own.
32.24%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-0508 (HER2) Details Solid tumor/s, Cancer | Failed Discontinued | |
CT-0525 Details Solid tumor/s, Cancer | Failed Discontinued | |
CT-0508 (HER2) + pembrolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
Vicineum™ Details Bladder cancer, Cancer | Failed Discontinued | |
Vicineum™ Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued |